Literature DB >> 15356293

Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor.

Stephen W Mason1, Carol Lawetz, Yvon Gaudette, Florence Dô, Erika Scouten, Lisette Lagacé, Bruno Simoneau, Michel Liuzzi.   

Abstract

RNA-dependent RNA polymerase from respiratory syncytial virus (RSV) is a multi-subunit ribonucleoprotein (RNP) complex that, in addition to synthesizing the full 15 222 nt viral genomic RNA, is able to synthesize all 10 viral mRNAs. We have prepared crude RNP from RSV-infected HEp-2 cells, based on a method previously used for Newcastle disease virus, and established a novel polyadenylation-dependent capture [poly(A) capture] assay to screen for potential inhibitors of RSV transcriptase activity. In this homogeneous assay, radiolabeled full-length polyadenylated mRNAs produced by the viral RNP are detected through capture on immobilized biotinylated oligo(dT) in a 96-well streptavidin-coated FlashPlate. Possible inhibitors identified with this assay could interfere at any step required for the production of complete RSV mRNAs, including transcription, polyadenylation and, potentially, co-transcriptional guanylylation. A specific inhibitor of RSV transcriptase with antiviral activity was identified through screening of this assay.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356293      PMCID: PMC519107          DOI: 10.1093/nar/gkh809

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  41 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  Influenza A virus RNA polymerase has the ability to stutter at the polyadenylation site of a viral RNA template during RNA replication.

Authors:  H Zheng; H A Lee; P Palese; A García-Sastre
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  FlashPlate scintillation proximity assays for characterization and screening of DNA polymerase, primase, and helicase activities.

Authors:  D L Earnshaw; A J Pope
Journal:  J Biomol Screen       Date:  2001-02

4.  Identification of protein regions involved in the interaction of human respiratory syncytial virus phosphoprotein and nucleoprotein: significance for nucleocapsid assembly and formation of cytoplasmic inclusions.

Authors:  B García-Barreno; T Delgado; J A Melero
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

5.  Requirement of casein kinase II-mediated phosphorylation for the transcriptional activity of human respiratory syncytial viral phosphoprotein P: transdominant negative phenotype of phosphorylation-defective P mutants.

Authors:  B Mazumder; S Barik
Journal:  Virology       Date:  1994-11-15       Impact factor: 3.616

Review 6.  Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).

Authors:  Jessie R Groothuis; Hiroshi Nishida
Journal:  Pediatr Int       Date:  2002-06       Impact factor: 1.524

Review 7.  An update on respiratory syncytial virus antiviral agents.

Authors:  G A Prince
Journal:  Expert Opin Investig Drugs       Date:  2001-02       Impact factor: 6.206

8.  Transcriptive complex of Newcastle disease virus. II. Structural and functional assembly associated with the cytoskeletal framework.

Authors:  M Hamaguchi; K Nishikawa; T Toyoda; T Yoshida; T Hanaichi; Y Nagai
Journal:  Virology       Date:  1985-12       Impact factor: 3.616

9.  Mapping the domains on the phosphoprotein of bovine respiratory syncytial virus required for N-P interaction using a two-hybrid system.

Authors:  S K Mallipeddi; B Lupiani; S K Samal
Journal:  J Gen Virol       Date:  1996-05       Impact factor: 3.891

10.  Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate.

Authors:  Ginette McKercher; Pierre L Beaulieu; Daniel Lamarre; Steven LaPlante; Sylvain Lefebvre; Charles Pellerin; Louise Thauvette; George Kukolj
Journal:  Nucleic Acids Res       Date:  2004-01-22       Impact factor: 16.971

View more
  19 in total

1.  Mutational analysis reveals a noncontractile but interactive role of actin and profilin in viral RNA-dependent RNA synthesis.

Authors:  Mary Harpen; Tiasha Barik; Alla Musiyenko; Sailen Barik
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

2.  Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

Authors:  John P DeVincenzo; Tom Wilkinson; Akshay Vaishnaw; Jeff Cehelsky; Rachel Meyers; Saraswathy Nochur; Lisa Harrison; Patricia Meeking; Alex Mann; Elizabeth Moane; John Oxford; Rajat Pareek; Ryves Moore; Ed Walsh; Robert Studholme; Preston Dorsett; Rene Alvarez; Robert Lambkin-Williams
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

3.  Respiratory Syncytial Virus Inhibitor AZ-27 Differentially Inhibits Different Polymerase Activities at the Promoter.

Authors:  Sarah L Noton; Kartikeya Nagendra; Ewan F Dunn; Michael E Mawhorter; Qin Yu; Rachel Fearns
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

4.  A high-throughput screening strategy to overcome virus instability.

Authors:  Lynn Rasmussen; Clinton Maddox; Blake P Moore; William Severson; E Lucile White
Journal:  Assay Drug Dev Technol       Date:  2010-11-04       Impact factor: 1.738

5.  Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase.

Authors:  Michel Liuzzi; Stephen W Mason; Mireille Cartier; Carol Lawetz; Robert S McCollum; Nathalie Dansereau; Gordon Bolger; Nicole Lapeyre; Yvon Gaudette; Lisette Lagacé; Marie-Josée Massariol; Florence Dô; Paul Whitehead; Lyne Lamarre; Erika Scouten; Josée Bordeleau; Serge Landry; Jean Rancourt; Gulrez Fazal; Bruno Simoneau
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Mechanism of action for respiratory syncytial virus inhibitor RSV604.

Authors:  SreeRupa Challa; Andrew D Scott; Olga Yuzhakov; Ying Zhou; Choi Lai Tiong-Yip; Ning Gao; Jason Thresher; Qin Yu
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

Review 7.  Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.

Authors:  Kerry M Empey; R Stokes Peebles; Jay K Kolls
Journal:  Clin Infect Dis       Date:  2010-05-01       Impact factor: 9.079

8.  Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.

Authors:  Matthew Coates; Daniel Brookes; Young-In Kim; Heather Allen; Euan A F Fordyce; Elizabeth A Meals; Thomas Colley; Claire-Lise Ciana; Guillaume F Parra; Vladimir Sherbukhin; Jennifer A Stockwell; Jennifer C Thomas; S Fraser Hunt; Lauren Anderson-Dring; Stuart T Onions; Lindsey Cass; Peter J Murray; Kazuhiro Ito; Pete Strong; John P DeVincenzo; Garth Rapeport
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

9.  Characterization of a respiratory syncytial virus L protein inhibitor.

Authors:  Choi-Lai Tiong-Yip; Lisa Aschenbrenner; Kenneth D Johnson; Robert E McLaughlin; Jun Fan; SreeRupa Challa; Hui Xiong; Qin Yu
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

10.  Inhibition of human parainfluenza virus type 3 infection by novel small molecules.

Authors:  Hongxia Mao; Chandar S Thakur; Santanu Chattopadhyay; Robert H Silverman; Andrei Gudkov; Amiya K Banerjee
Journal:  Antiviral Res       Date:  2007-10-02       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.